Skip To Main Content
Conor Hale on Muck Rack

Conor Hale

Verified
Washington, D.C.
As seen in: Fierce Biotech, Fierce Pharma, Questex Media Group, NewsBreak, Fierce Healthcare, CenterWatch, Cyber Era
Writing and reporting on medical developments for @FierceMedTech and @FierceBiotech

Get in touch with Conor

Contact Conor, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Johnson & Johnson’s Impella pumps miss the mark in 2 major coronary studies

|
By Conor Hale Verified
| Fierce Biotech Verified
Two separate randomized trials of Johnson & Johnson’s miniaturized Impella heart pumps failed to illustrate the devices’ benefits, spanning specific cases in patients with blockages in their coronary arteries—including interventions both ahead of and after they’ve suffered a severe heart attack.
Open in Who Shared Issue with article?

Boston Scientific’s Watchman heart implant measures up to blood thinners in ACC trial

|
By Conor Hale Verified
| Fierce Biotech Verified
In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thinners among people looking to reduce their lifetime risk of stroke due to an abnormal heart rhythm. Atrial fibrillation is the most common arrhythmia, and is estimated to affect nearly 5% of the U.S. population.
Open in Who Shared View Duplicates (2) Issue with article?

After local tumor approval, Novocure touts positive data in metastatic pancreatic cancer

|
By Conor Hale Verified
| Fierce Biotech Verified
After collecting an FDA approval earlier this year for local pancreatic cancer, Novocure is putting forward positive clinical data for its electric field-based treatment in metastatic cases of the aggressive disease. A phase 2 trial evaluated the company’s wearable device in a first-line approach for metastatic pancreatic ductal adenocarcinoma, alongside a drug regimen adding Genentech’s Tecentriq to a combination of gemcitabine and nab-paclitaxel.
Open in Who Shared View Duplicates (2) Issue with article?
See all 3,339 licensed articles (4,574 Total)